Treatment of COVID-19 exacerbated asthma: should systemic corticosteroids be used?

Treatment of COVID-19 exacerbated asthma: should systemic corticosteroids be used?

Publication date: May 13, 2020

Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 infection is a new rapidly spreading infectious disease. Current guidance from the World Health Organisation (WHO) highlights asthmatics as a high-risk group for severe illness from COVID-19. Viruses are common triggers of asthma exacerbations and the current SARS-CoV-2 pandemic raises several questions regarding the optimum management strategies. Here, we discuss the contentious issue of whether the mainstay therapies systemic corticosteroids should be used in the routine management of COVID-19-associated asthma exacerbations. Recent guidance from the WHO has advised against the use of corticosteroids if COVID-19 is suspected due to concerns that these agents may impair protective innate anti-viral immune responses. This may not be appropriate in the unique case of asthma exacerbation, a syndrome associated with augmented type 2 inflammation, a disease feature that is known to directly inhibit anti-viral immunity. Corticosteroids, through their suppressive effects on type 2 inflammation, are thus likely to restore impaired anti-viral immunity in asthma and, in contrast to non-asthmatic subjects, have beneficial clinical effects in the context of SARS-CoV-2 infection.

Concepts Keywords
Asthma Coronaviridae
Asthmatic Asthma
Coronavirus Respiratory therapy
Corticosteroids Viruses
Immunity Medicine
Infection Respiratory diseases
Infectious Disease Inflammation
Inflammation Associated asthma
Pandemic SARS
SARS Infection
Syndrome Asthmatics high risk
Viral Corticosteroid
WHO Coronavirus
Asthma-related microbes

Semantics

Type Source Name
disease MESH asthma
pathway KEGG Asthma
disease MESH infection
disease MESH infectious disease
disease MESH syndrome
disease MESH inflammation

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *